Lucy Ziegler

Lucy Ziegler

Auto-generated profile, based on publicly available information

Lucy Ziegler

Academic Unit of Palliative Care, University of Leeds, Leeds, UK

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2020 in Palliative Medicine
Verified
Journal Article
Open access
PDF file
YEYousuf ElMokhallalati
Yousuf ElMokhallalati
SBStephen H Bradley
Stephen H Bradley
ECEmma Chapman
Emma Chapman
LZLucy Ziegler
Lucy Ziegler
FMFliss Em Murtagh
Fliss Em Murtagh
MBMichael I Bennett
Michael I Bennett
Background: Despite increasing evidence of the benefits of early access to palliative care, many patients do not receive palliative care in a timely manner. A systematic approach in primary care can facilitate earlier identification of patients with potential palliative care needs and prompt further assessment. Aim: To identify existing screening tools for identification of patients with advanced progressive diseases who are likely to have palliative care needs in primary healthcare and evaluate their accuracy. Design: Systematic review (PROSPERO registration number CRD42019111568). Data sources: Cochrane, MEDLINE, Embase and CINAHL were searched from inception to March 2019 Results: From 4,127 unique articles screened, 25 reported the use or development of 10 screening tools. Most tools use prediction of death and/or deterioration as a proxy for the identification of people with potential palliative care needs. The tools are based on a wide range of general and disease-specific indicators. The accuracy of five tools was assessed in eight studies; these tools differed significantly in their ability to identify patients with potential palliative care needs with sensitivity ranging from 3% to 94% and specificity ranging from 26% to 99%. Conclusion: The ability of current screening tools to identify patients with advanced progressive diseases who are likely to have palliative care needs in primary care is limited. Further research is needed to identify standardised screening processes that are based not only on predicting mortality and deterioration but also on anticipating the palliative care needs and predicting the rate and course of functional decline. This would prompt a comprehensive assessment to identify and meet their needs on time.

6 June 2018 in Palliative Medicine
Verified
Journal Article
Open access
MAMatthew Allsop
Matthew Allsop
LZLucy E Ziegler
Lucy E Ziegler
MMMatthew Mulvey
Matthew Mulvey
SRSarah Russell
Sarah Russell
RTRos Taylor
Ros Taylor
MBMichael I Bennett
Michael I Bennett
Understanding service provision for patients with advanced disease is a research priority, with a need to identify barriers that limit widespread integration of palliative care. To identify patient and organisational factors that influence the duration of hospice-based palliative care in the United Kingdom prior to death. This is a retrospective cohort study. A total of 64 UK hospices providing specialist palliative care inpatient beds and community services extracted data for all adult decedents (aged over 17 years) with progressive, advanced disease, with a prior referral (e.g. inpatient, community teams, and outpatient) who died between 1 January 2015 and 31 December 2015. Data were requested for factors relating to both the patient and hospice site. Across 42,758 decedents, the median time from referral to death was 48 days. Significant differences in referral to death days were found for those with cancer (53 days) and non-cancer (27 days) (p < 0.0001). As age increases, the median days from referral to death decreases: for those under 50 years (78 days), 50–74 years (59 days), and 75 years and over (39 days) (p = 0.0001). An adjusted multivariable negative binomial model demonstrated increasing age persisting as a significant predictor of fewer days of hospice care, as did being male, having a missing ethnicity classification and having a non-cancer diagnosis (p < 0.001). Despite increasing rhetoric around early referral, patients with advanced disease are receiving referrals to hospice specialist palliative care very late in their illness trajectory. Age and diagnosis persist as determinants of duration of hospice specialist palliative care before death.

23 June 2017 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
PHP. Holch
P. Holch
LWL. Warrington
L. Warrington
LBL. C. A. Bamforth
L. C. A. Bamforth
AKA. Keding
A. Keding
LZL. E. Ziegler
L. E. Ziegler
GVG. Velikova
G. Velikova
Significant adverse events (AE) during cancer therapy disrupt treatment and escalate to emergency admissions. Approaches to improve the timeliness and accuracy of AE reporting may improve safety and reduce health service costs. Reporting AE via patient reported outcomes (PROs), can improve clinician–patient communication and making data available to clinicians in ‘real-time’ using electronic PROs (ePROs) could potentially transform clinical practice by providing easily accessible records to guide treatment decisions. This manuscript describes the development of eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and aDvice) is a National Institute for Health Research-funded programme, a system for patients to self-report and manage AE online during and after cancer treatment. A multidisciplinary team of IT experts, staff and patients developed using agile principles a secure web application interface (QStore) between an existing online questionnaire builder (QTool) displaying real-time ePRO data to clinicians in the electronic patient record at Leeds Teaching Hospitals NHS Trust. Hierarchical algorithms were developed corresponding to Common Terminology Criteria for Adverse Events grading using the QTool question dependency function. Patient advocates (N = 9), patients (N = 13), and staff (N = 19) usability tested the system reporting combinations of AE. The eRAPID system allows patients to report AE from home on PC, tablet or any web enabled device securely during treatment. The system generates immediate self-management advice for low or moderate AE and for severe AE advice to contact the hospital immediately. Clinicians can view patient AE data in the electronic patient record and receive email notifications when patients report severe AE. Evaluation of the system in a randomised controlled trial in breast, gynaecological and colorectal cancer patients undergoing systemic therapy is currently underway. To adapt eRAPID for different treatment groups, pilot studies are being undertaken with patients receiving pelvic radiotherapy and upper gastrointestinal surgery. ISRCTN88520246.

1 July 2011 in European Journal of Oncology Nursing
Verified
Journal Article
Closed access
SBS.G. Brearley
S.G. Brearley
ZSZ. Stamataki
Z. Stamataki
JAJ. Addington-Hall
J. Addington-Hall
CFC. Foster
C. Foster
LHL. Hodges
L. Hodges
ZAZ. Amir
Z. Amir

31 January 2018 in BMJ Open
Verified
Journal Article
Open access
LZLucy E Ziegler
Lucy E Ziegler
CCCheryl L Craigs
Cheryl L Craigs
RWRobert M West
Robert M West
PCPaul Carder
Paul Carder
AHAdam Hurlow
Adam Hurlow
MBMichael I Bennett
Michael I Bennett
Objectives This study aimed to establish the association between timing and provision of palliative care (PC) and quality of end-of-life care indicators in a population of patients dying of cancer. Setting This study uses linked cancer patient data from the National Cancer Registry, the electronic medical record system used in primary care (SystmOne) and the electronic medical record system used within a specialist regional cancer centre. The population resided in a single city in Northern England. Participants Retrospective data from 2479 adult cancer decedents who died between January 2010 and February 2012 were registered with a primary care provider using the SystmOne electronic health record system, and cancer was certified as a cause of death, were included in the study. Results Linkage yielded data on 2479 cancer decedents, with 64.5% who received at least one PC event. Decedents who received PC were significantly more likely to die in a hospice (39.4% vs 14.5%, P<0.005) and less likely to die in hospital (23.3% vs 40.1%, P<0.05), and were more likely to receive an opioid (53% vs 25.2%, P<0.001). PC initiated more than 2 weeks before death was associated with avoiding a hospital death (≥2 weeks, P<0.001), more than 4 weeks before death was associated with avoiding emergency hospital admissions and increased access to an opioid (≥4 weeks, P<0.001), and more than 33 weeks before death was associated with avoiding late chemotherapy (≥33 weeks, no chemotherapy P=0.019, chemotherapy over 4 weeks P=0.007). Conclusion For decedents with advanced cancer, access to PC and longer duration of PC were significantly associated with better end-of-life quality indicators.

9 September 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
STSally Taylor
Sally Taylor
CHClare Harley
Clare Harley
LZLucy Ziegler
Lucy Ziegler
JBJulia Brown
Julia Brown
GVGalina Velikova
Galina Velikova